Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- DMYD-B.ST
- Price
- 7.82
- Stock movement up
- +0.02 (0.26%)
- Company name
- Diamyd Medical AB (publ)
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 790.60M
- Ent value
- 748.96M
- Price/Sales
- 6081.55
- Price/Book
- 5.42
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 23.41%
- 1 year return
- -24.95%
- 3 year return
- -22.87%
- 5 year return
- -16.99%
- 10 year return
- -3.40%
Last updated: 2025-04-18
DIVIDENDS
DMYD-B.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6081.55 |
| Price to Book | 5.42 |
| EV to Sales | 5761.25 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 101.10M |
| EPS (TTM) | -1.52 |
| FCF per share (TTM) | -1.38 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 130.00K |
| Gross profit (TTM) | -28.77M |
| Operating income (TTM) | -145.44M |
| Net income (TTM) | -151.85M |
| EPS (TTM) | -1.52 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -22134.62% |
| Operating margin (TTM) | -111879.23% |
| Profit margin (TTM) | -116806.92% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 112.76M |
| Net receivables | 23.00K |
| Total current assets | 159.14M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 217.04M |
| Accounts payable | 16.61M |
| Short/Current long term debt | 30.67M |
| Total current liabilities | 40.02M |
| Total liabilities | 71.12M |
| Shareholder's equity | 145.92M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -129.18M |
| Capital expenditures (TTM) | 8.03M |
| Free cash flow (TTM) | -137.21M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -104.06% |
| Return on Assets | -69.96% |
| Return on Invested Capital | -104.06% |
| Cash Return on Invested Capital | -94.03% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.75 |
| Daily high | 8.05 |
| Daily low | 7.64 |
| Daily Volume | 357K |
| All-time high | 71.00 |
| 1y analyst estimate | 40.00 |
| Beta | 2.14 |
| EPS (TTM) | -1.52 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| DMYD-B.ST | S&P500 | |
| Current price drop from All-time high | -88.99% | -14.12% |
| Highest price drop | -90.75% | -56.47% |
| Date of highest drop | 29 Dec 2023 | 9 Mar 2009 |
| Avg drop from high | -58.66% | -11.07% |
| Avg time to new high | 76 days | 12 days |
| Max time to new high | 1195 days | 1805 days |
COMPANY DETAILS
Marketcap
790.60M
Marketcap category
Small-cap
Description
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was founded in 1984 and is headquartered in Stockholm, Sweden.
Employees
27
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Diamyd Medical today announced a successful interim analysis (non-futility test) for its ongoing precision medicine Phase 3 DIAGNODE-3 trial. The interim analysis, reviewed by an independent Data Safe...
July 30, 2024
Diamyd Medical announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd® (rhGAD65/alum) to treat Type 1 Diabetes in pediatric patients with Stage ...
July 18, 2024